Saturday 17 October 2026 Export DCOY’s income statement to Excel — free account

Decoy Therapeutics Inc

In the quarter to June 2026, revenue fell 84.6%, EPS grew 94.5% and free cash flow fell 212.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

1.17 0.06 −4.88%

Follow DCOY

Alert me

Market cap: $2.9M
P/E: 0.0×
Fwd P/E: −2.5×
Dividend yield: —
F-score: 4/9
Altman Z: 4.31
Beneish M: n/a
Dividend safety: n/a

Overview Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.02

Total sells 0.00

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	2	—	—	—	—	—	—	—	—	—	—	—
Sell	—	1	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 2.93

Revenue 2.07

Net Income (14.45)

Free Cash Flow (8.94)

Net Debt (8.29)

Current Ratio 1.83

Debt/Equity 0.00

P/E ratio 0.01

Fwd P/E (2.45)

P/S ratio 0.30

P/B ratio 0.14

Past 5Y EPS Growth —

This Y EPS Growth 77.55%

Next Y EPS Growth (48.48%)

Next Y revenue growth (100.00%)

Next 5Y EPS Growth 80.05%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 8.22%

10-year low 10-year high

P/B against its own 10 years 2.85%

10-year low 10-year high

EV/FCF against its own 10 years 64.25%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	6	2	11	8
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	7	3	11	9

	2023	2024	2025	Q'26
Payables	1	1	1	1
ST’ Debt	—	—	—	—
Other	—	—	0	—
	1	2	5	5

Compound Annual Growth %

	10y	5y	3y
Sales	—	12.73%	(1.94%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(24.05%)	(23.28%)	(17.23%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	0	—	—	—
’21	1	1	—	0	2
’20	1	1	1	1	5
’19	1	1	1	1	3
’18	0	0	0	1	2
’17	0	0	0	0	1

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(3)	—	—	—
’25	(1)	(1)	(2)	(1)	(5)
’24	(1)	(1)	(1)	(1)	(5)
’23	(3)	(4)	(4)	(2)	(13)
’22	(4)	(4)	(6)	(5)	(18)
’21	(3)	(3)	(2)	(3)	(10)
’20	(4)	(2)	(3)	(1)	(10)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(3)	—	—	—
’25	(1)	(1)	(2)	(2)	(5)
’24	(1)	(1)	(1)	(1)	(5)
’23	(3)	(4)	(4)	(2)	(13)
’22	(5)	(4)	(6)	(5)	(19)
’21	(3)	(3)	(2)	(3)	(10)
’20	(4)	(2)	(3)	(1)	(10)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(4.18)	(4.46)	—	—	—
’25	(185.38)	(80.99)	(21.73)	213.96	(129.10)
’24	(590.34)	(426.56)	(136.79)	(118.79)	(69.54)
’23	(3.21k)	(2.06k)	(935.91)	(316.77)	(5.53k)
’22	(4.68k)	(3.24k)	(9.23k)	(4.07k)	(21.43k)
’21	(2.16k)	(2.52k)	(2.88k)	(3.24k)	(11.16k)
’20	(7.92k)	(4.68k)	(3.60k)	(3.60k)	(18.00k)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	4,090,500.00	2,412,000.00	234,000.00	104,760.00	19,980.00	17,316.00	1,540.80	756.00	219.60	7.44	Analyst estimates 2026–2028 Powerpack
	High	12,573,000.00	5,392,800.00	8,082,000.00	880,200.00	139,680.00	126,000.00	19,512.00	6,393.60	1,296.00	1,296.00
People
People	Employees	31	22	4	7	10	16	12	2	2	11
	Revenue/emp, $m	0.03	0.06	0.49	0.50	0.52	0.12	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	1	1	2	3	5	2	—	—	—	—
	Gross margin, %	34.42	60.26	100.00	100.00	100.00	100.00	0.00	—	—	—
	EBT	(39)	(34)	(2)	(7)	(7)	(13)	(32)	(13)	(6)	(13)
	EBT margin, %	(3,907.50)	(2,701.74)	(85.56)	(200.18)	(140.49)	(693.85)	0.00	0.00	0.00	0.00
	Net income	(39)	(34)	(2)	(7)	(7)	(13)	(32)	(13)	(6)	(13)
	Depreciation	0	0	0	0	0	0	0	0	0	0
Per share, $
Per share, $	Revenue	0.06	0.07	0.00	34,651.00	13,083.25	1,672.91	0.00	0.00	0.00	0.00
	Earnings	(2.43)	(1.99)	(1,097,891.00)	(76,312.38)	(17,998.21)	(11,158.89)	(21,425.06)	(5,529.05)	(69.54)	(129.10)
	Cash flow	(1.97)	(1.61)	0.00	(115,801.00)	(25,778.50)	(9,272.91)	(11,730.20)	(5,585.26)	(56.43)	(49.76)
	Capex	(0.03)	(0.01)	0.00	0.00	(6.50)	0.00	(1,000.00)	0.00	0.00	(5.95)
	Free cash flow	(2.01)	(1.61)	0.00	(115,801.00)	(25,785.00)	(9,272.91)	(12,730.20)	(5,585.26)	(56.43)	(55.71)
	Book value	3.65	1.69	0.00	105,809.00	55,398.00	35,202.73	6,923.07	2,298.83	18.85	60.71
	Shares, m	16	17	0	0	0	0	0	0	0	0
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—
	P/S	0.00	43,395,293.79	0.00	3.93	2.50	5.92	—	—	—	—
	P/B	1,320,233.46	1,900,060.21	0.00	1.29	0.59	0.51	—	—	—	—
	EV/Sales	0.00	43,395,267.64	(3.14)	3.06	0.47	(2.74)	—	—	—	—
	EV/FCF	(2,401,774.97)	(1,987,141.01)	(1.47)	(0.92)	(0.24)	0.89	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	(32)	(28)	4	(12)	(10)	(10)	(18)	(13)	(5)	(5)
	Capex	(1)	0	0	—	0	—	(1)	—	—	(1)
	Free cash flow	(33)	(28)	4	(12)	(10)	(10)	(19)	(13)	(5)	(5)
Balance, $m
Balance, $m	Working capital	59	29	(2)	1	14	28	10	5	1	6
	Total debt	—	—	—	1	0	—	—	—	—	—
	Net debt	(61)	(33)	(6)	(4)	(11)	(29)	(12)	(6)	(2)	(11)
	Shareholders’ equity	59	29	(1)	11	22	39	10	5	2	6
Returns, %
Returns, %	ROA	(49.90)	(70.12)	(8.62)	(67.64)	(39.91)	(38.83)	(113.93)	(118.12)	(116.05)	(177.82)
	ROIC	0.00	0.00	0.00	(75.50)	(42.25)	(84.22)	0.00	0.00	0.00	0.00
	ROE	(52.13)	(77.88)	(12.89)	(149.01)	(47.33)	(41.94)	(128.73)	(160.07)	(164.02)	(338.31)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2021 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
APVO Aptevo Therapeutics Inc.	$3.1M	0.0×	— (loss-making)	+28.62% (above 0%: growing)	n/m	+23.11% (above 0%: growing)	0.00%	0.00%	Compare
GRI GRI Bio, Inc.	$3.1M	0.0×	— (loss-making)	—	n/m	+54.33% (above 0%: growing)	0.00%	0.00%	Compare
REVB Revelation Biosciences, Inc.	$3.0M	— (loss-making)	—	—	n/m	−35.29% (below 0%: shrinking)	0.00%	0.00%	Compare
ARAV ARAVIVE, INC	$3.0M	— (loss-making)	— (loss-making)	−44.39% (below 0%: shrinking)	n/m	+48.19% (above 0%: growing)	100.00%	(323.44%)	Compare
DCOY Decoy Therapeutics Inc	$2.9M	0.0×	— (loss-making)	−84.61% (below 0%: shrinking)	n/m	−212.47% (below 0%: shrinking)	100.00%	(1,055.98%)
MBIO Mustang Bio, Inc.	$2.9M	— (loss-making)	—	—	n/m	+27.78% (above 0%: growing)	0.00%	0.00%	Compare
BCAB BioAtla, Inc.	$2.9M	— (loss-making)	— (loss-making)	+4,233.33% (above 0%: growing)	n/m	+97.03% (above 0%: growing)	100.00%	3.49%	Compare
ONCO Onconetix, Inc.	$2.9M	0.0×	— (loss-making)	−83.94% (below 0%: shrinking)	n/m	−36.00% (below 0%: shrinking)	25.15%	(15,969.59%)	Compare
VIVS VivoSim Labs, Inc.	$2.8M	— (loss-making)	— (loss-making)	−51.35% (below 0%: shrinking)	n/m	+17.87% (above 0%: growing)	100.00%	(15,327.78%)	Compare
Median of peers	$2.9M	0.0×	—	−44.39%	—	+25.45%	12.58%	0.00%

All 614 Biotechnology stocks →

Decoy Therapeutics Inc (DCOY) key facts

Decoy Therapeutics Inc (DCOY) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, DCOY traded at $1.17, a market capitalization of $2.9 million.
Return on equity was −338.3% and debt-to-equity 0.00.

Source: company filings (standardised) and stockrow calculations.